Aurinia Pharmaceuticals Inc (FRA:IKAP)
€ 8.542 -0.116 (-1.34%) Market Cap: 1.23 Bil Enterprise Value: 978.48 Mil PE Ratio: 0 PB Ratio: 3.30 GF Score: 81/100

Q4 2022 Aurinia Pharmaceuticals Inc Earnings Call Transcript

Feb 28, 2023 / 01:30PM GMT
Operator

Greetings, and welcome to the Aurinia Pharmaceuticals Inc. Fourth Quarter and 2022 Earnings Call. (Operator Instructions) As a reminder, this conference is being recorded.

I would now like to turn the conference over to your host, Jamie Harrell, Investor Relations for Aurinia Pharmaceuticals. Thank you. You may begin.

Jamie Harrell

Thank you, operator, and thank you all for joining today's call and webcast to discuss Aurinia's fourth quarter and full year 2022 financial and operational results. Joining me this morning are Peter Greenleaf, Chief Executive Officer; and Joe Miller, Chief Financial Officer. This morning, Aurinia issued a press release announcing its final audited financial results for the fourth quarter and full year ending December 31, 2022, as well as its recent operational highlights. In addition, the company filed its annual financial statements on Form 10-K. For more information, please refer to Aurinia's filings with the U.S. Securities and Exchange Commission, which are also available on Aurinia's website at auriniapharma.com.

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot